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REVIEW
Treatment strategies for new onset atrial 
fibrillation in patients treated on an intensive 
care unit: a systematic scoping review
Laura Drikite2* , Jonathan P. Bedford1, Liam O’Bryan1, Tatjana Petrinic4, Kim Rajappan6, James Doidge2, 
David A. Harrison2, Kathryn M. Rowan2, Paul R. Mouncey2, Duncan Young1, Peter J. Watkinson3 and 
Mark Corbett5 
Abstract 
Background: New-onset atrial fibrillation (NOAF) in patients treated on an intensive care unit (ICU) is common and 
associated with significant morbidity and mortality. We undertook a systematic scoping review to summarise com-
parative evidence to inform NOAF management for patients admitted to ICU.
Methods: We searched MEDLINE, EMBASE, CINAHL, Web of Science, OpenGrey, Cochrane Database of Systematic 
Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, ISRCTN, Clini-
calTrials.gov, EU Clinical Trials register, additional WHO ICTRP trial databases, and NIHR Clinical Trials Gateway in 
March 2019. We included studies evaluating treatment or prevention strategies for NOAF or acute anticoagulation 
in general medical, surgical or mixed adult ICUs. We extracted study details, population characteristics, intervention 
and comparator(s), methods addressing confounding, results, and recommendations for future research onto study-
specific forms.
Results: Of 3,651 citations, 42 articles were eligible: 25 primary studies, 12 review articles and 5 surveys/opinion 
papers. Definitions of NOAF varied between NOAF lasting 30 s to NOAF lasting > 24 h. Only one comparative study 
investigated effects of anticoagulation. Evidence from small RCTs suggests calcium channel blockers (CCBs) result in 
slower rhythm control than beta blockers (1 study), and more cardiovascular instability than amiodarone (1 study). 
Evidence from 4 non-randomised studies suggests beta blocker and amiodarone therapy may be equivalent in 
respect to rhythm control. Beta blockers may be associated with improved survival compared to amiodarone, CCBs, 
and digoxin, though supporting evidence is subject to confounding. Currently, the limited evidence does not support 
therapeutic anticoagulation during ICU admission.
Conclusions: From the limited evidence available beta blockers or amiodarone may be superior to CCBs as first line 
therapy in undifferentiated patients in ICU. The little evidence available does not support therapeutic anticoagulation 
for NOAF whilst patients are critically ill. Consensus definitions for NOAF, rate and rhythm control are needed.
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Background
New onset atrial fibrillation (NOAF), usually defined 
as atrial fibrillation (AF) occurring in patients with no 
known history of AF [1], is a common arrhythmia in crit-
ically ill patients [2]. NOAF occurs in 5–11% of patients 
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admitted to an intensive care unit (ICU) [3–6], and up to 
46% of patients with septic shock [7, 8]. NOAF in criti-
cally ill patients can cause cardiovascular instability [5] 
and is associated with increased risk of thromboembo-
lism [9], increased mortality [10] and length of ICU stay 
[11], and higher healthcare costs [11].
Guidelines for management of AF [12, 13] do not 
directly apply to critically ill patients. NOAF in patients 
treated on an ICU differs from AF in patients in the com-
munity in terms of causes of rhythm disturbance [14, 15], 
risks and effectiveness of treatments [16]. The lack of evi-
dence for managing NOAF in patients treated on an ICU 
means treatment practice differs widely [17].
We conducted a scoping review to provide an overview 
of current evidence for the effectiveness and safety of 
pharmacological, electrical, and other non-pharmacolog-
ical NOAF treatments, prophylactic strategies, and acute 
anticoagulation for stroke prophylaxis in critically ill 
patients. We also aimed to describe commonly used defi-
nitions of NOAF in patients treated on an ICU and sug-
gest recommendations and barriers for future research.
A recent scoping review described the incidence, risk 
factors, outcomes and management strategies related to 
NOAF during critical illness [10]. It included patients 
with pre-existing AF and studies conducted outside 
ICUs. Our review focusses on the comparative evidence 
for treatment of NOAF in patients treated on an ICU.
Materials and methods
Search and identification of studies
We developed our search strategy with an information 
specialist (TP) in MEDLINE with no date or language 
restrictions. We included terms used for NOAF com-
bined with terms used for intensive care (see Additional 
file 1).
We adapted the MEDLINE search strategy to identify 
papers in the following databases in March 2019: MED-
LINE, EMBASE, CINAHL, Web of Science (including 
Conference Proceedings Citation Index: Science), Open-
Grey, the Cochrane Database of Systematic Reviews, 
the Cochrane Central Register of Controlled Trials 
(CENTRAL), and the Database of Abstracts of Reviews 
of Effects (DARE) to 2015. The following clinical trial 
databases were searched for studies in progress, or com-
pleted but not reported: ISRCTN, ClinicalTrials.gov, the 
EU Clinical Trials register, additional WHO ICTRP trial 
databases, and the NIHR Clinical Trials Gateway.
Eligibility criteria
We included studies of adults (age ≥ 16 years) in general 
medical, surgical or mixed ICUs. We excluded stud-
ies of cohorts defined by a single disease or narrow dis-
ease group not normally admitted to a general ICU, and 
studies based on service-specific ICUs. We included 
studies of pharmacological, electrical and other non-
pharmacological treatment strategies for treatment or 
prophylaxis of NOAF and the use of acute anticoagula-
tion. The outcomes of interest were rhythm and rate 
control, length of ICU and hospital stay, mortality (ICU, 
hospital, 30-day, long term), arterial thromboembo-
lism and adverse treatment effects. Quantitative studies, 
reviews, practitioner surveys, and opinion pieces were 
eligible for this review.
Study selection and data charting
We used EPPI-Reviewer 4 software (Evidence for Policy 
and Practice Information and Co-ordinating Centre, 
University of London, London, UK) to identify duplicate 
records and for title and abstract screening. Two review-
ers (LD and LOB) independently screened titles, abstracts 
and full-text articles, with discrepancies resolved through 
discussion or by a third reviewer (MC).
We also reviewed reference lists of included studies for 
further relevant citations. Full-text articles not published 
in English were screened by native speakers.
We developed data charting forms (see Additional 
file  1: Tables S1–S10) for the following study designs: 
randomised controlled trials (RCTs), prospective com-
parative studies, retrospective comparative studies, and 
non-comparative studies. The extracted data included: 
details of the study, population characteristics, descrip-
tion of intervention and comparator(s), methods to 
address confounding, results, and recommendations for 
future research.
Decisions about which population characteristics to 
extract were informed by a systematic review on risk 
factors for NOAF on the ICU [18] and a retrospective 
observational study on predictors for sustained NOAF in 
the critically ill [19]. Data were extracted by one reviewer 
(LD) and checked by another (JB); disagreements were 
referred to a third reviewer (MC).
Critical appraisal
We evaluated RCTs using version 2 of the Cochrane risk 
of bias tool [20]. We evaluated non-randomised compar-
ative studies for risk of bias using the ROBINS-I tool [21] 
if they were reported as full papers, included at least 100 
patients per treatment arm and reported on methods to 
adjust for confounding.
Studies which did not meet these criteria were deemed 
to be at a critical risk of bias. The ROBINS-I tool was 
adapted by including a stopping rule: the assessment 
stopped if a serious, or critical, risk of bias judgement 
was made for the ‘bias due to confounding’ domain. For 
the confounding domain, decisions regarding which 
covariates should be reported as being controlled for in 
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analyses were made by the clinical experts in the CAFE 
study team and are reported in Additional file  1 along 
with the risk of bias judgements (see Additional file  1: 
Tables S11).
Collating and summarising results
We presented details of the primary studies in structured 
tables categorised by pairwise drug comparison and by 
study design. For each type of study design, we described 
the extent, range and nature of the identified research. 




Of the 3651 articles screened on title and abstract, 198 
articles were identified as being of potential interest and 
screened on full text. After full text screening, 42 arti-
cles were included in the review: 25 primary studies, 12 
review articles and 5 surveys/opinion papers. Of the 25 
primary studies, two RCTs [22, 23] two prospective com-
parative studies [24, 25], nine retrospective comparative 
studies [26–34] and 12 non-comparative studies [5, 35–
45] were included. Six studies [27–30, 32, 39] were avail-
able only as conference abstracts. Figure 1 illustrates the 
flow of the articles through the review process.
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Fig. 1 Flow chart showing the number of studies identified, excluded and eligible for inclusion in the scoping review
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Characteristics of included studies
Nine studies [22, 24, 27, 31, 35, 37, 41, 43, 44] were con-
ducted in speciality ICUs such as surgical, trauma, or 
medical. Five studies [5, 23, 38, 42, 45] were conducted 
in mixed ICUs and one study [26] in a general ICU. The 
type of ICU was not specified in 10 studies [25, 28–30, 
32–34, 36, 39, 40]. Eleven studies included patients with 
sepsis [5, 27, 28, 33–35, 38, 43] or septic shock [25, 26, 
29] as primary diagnoses. Four studies [22, 24, 31, 41] 
were conducted in a noncardiac surgical population. Two 
studies included noncardiac and cardiac surgery patients 
[37, 44] and one study was conducted in surgical popula-
tion; however, the type of surgery was not specified [40].
Nineteen studies [5, 22–24, 26–28, 30–33, 35, 36, 38, 
40, 41, 43–45] investigated the treatment effects of phar-
macological treatments, two studies [25, 29] looked at 
prophylactic treatments, and two studies [37, 42] inves-
tigated electrical treatments. One study [39] reported on 
both pharmacological treatments and anticoagulation for 
stroke prophylaxis. One study [34] on anticoagulation 
was included in the review.
Overview of the primary study evidence by interven-
tion and study design can be found in Additional file 1: 
Tables S12.
Definitions used for NOAF
Studies varied in how they reported and defined NOAF. 
Five studies [5, 31, 35, 37, 44] defined NOAF as having 
AF with a heart rate of > 100 beats per minute and two 
studies [23, 32] used a heart rate threshold of > 120 beats 
per minute. Seven studies [22, 23, 25, 35, 37, 43, 44] 
reported different time periods for which NOAF must be 
sustained, ranging from 30  s to 24  h. Six studies [5, 31, 
33, 34, 40, 42] specified in which instances AF would be 
considered as ‘new onset’. For example, when a patient 
had no prior history of AF [31], without previous history 
of atrial tachyarrhythmias and antiarrhythmic drug use 
[40], and AF not present on admission [33, 34]. Ten stud-




Six retrospective comparative studies [26, 28, 30–33] 
compared amiodarone with beta blockers (Table 1, Addi-
tional file  1: Tables S5 and S6). Most studies did not 
report on doses [28, 31–33] or modes of administration 
[28, 31, 32]. A large study [33] of 39,693 patients with 
sepsis reported that patients treated with amiodarone 
were more likely to be critically ill with septic shock than 
patients treated with beta blockers. After adjustment for 
confounding, beta blockers were associated with lower 
mortality than amiodarone (RR 0.67, 95% CI: 0.59–0.77) 
[33]. However, only 60% of patients were on an ICU. 
Therefore, this study’s results may not be applicable to 
a broad ICU population. The study was also judged as 
being at a serious risk of bias due to confounding (Addi-
tional file 1). Balik et al. [26] showed higher but not sta-
tistically significant ICU mortality in patients receiving 
amiodarone (40%) than in patients receiving metoprolol 
(21%) [26]. A conference abstract by Jaffer et al. [28] also 
reported no statistically significant difference in mortal-
ity. Four studies [26, 30–32] compared conversion rates 
between amiodarone and beta-blockers. Three studies 
[26, 30, 32] showed no statistically significant difference 
in cardioversion rates between the treatments. Balik et al. 
[26] did not adjust for confounding factors such as illness 
severity [26]. Two studies did not report on the methods 
used for the analysis [30, 32]. No meaningful conclusions 
from the results of Brown et al. could be made with only 
6 patients receiving amiodarone [31]. Figure  2 shows 
rhythm control risk ratio results for studies comparing 
amiodarone with beta blockers. Although Fig. 2 enables 
a crude comparison of results, the studies were too het-
erogeneous for this to depict a true comparison. It should 
also be noted that only studies which reported numera-
tors and denominators for the rhythm control outcome 
could be included in Fig. 2.
Amiodarone versus calcium channel blockers
One RCT [23], one prospective [24] and three retrospec-
tive comparative studies [28, 31, 32] compared amiodar-
one and calcium channel blockers (Table  2, Additional 
file 1: Tables S1, S2, S3, S4, S5, and S6), all were relatively 
small with between eight and 61 patients included.
A small RCT of 60 patients compared diltiazem, ami-
odarone bolus and amiodarone bolus followed by an 
amiodarone infusion in a mixed ICU population [23]. 
No evidence of a difference was identified between 
treatment groups in the primary study endpoint of rate 
reduction ≥ 30% at 4  h. Hypotension resulting in drug 
discontinuation was more common with diltiazem 
use (30%) vs amiodarone (0–5%). This study [23] was 
judged to have a high risk of bias. A non-randomised 
study comparing diltiazem and amiodarone in a non-
cardiac surgical ICU population found no evidence of 
differences between the study groups in the propor-
tion cardioverted at 24  h or in time to cardioversion 
[24]. No evidence of a difference in rates of hypoten-
sion was identified. Similar length of ICU and hospital 
stays was also reported. This study [24] was small and 
most likely underpowered to detect any treatment dif-
ferences. A conference abstract found no statistically 
significant difference in mortality at discharge [28]. 
Two studies [31, 32] compared rate and rhythm control 





























Table 1 Studies comparing amiodarone and beta blockers
a Includes calcium channel blockers and digoxin groups
b Relative risk
c Statistically not significant
d Includes propafenone group
e Includes calcium channel blockers and no treatment groups
Authors Sample size and 
setting
Primary diagnosis Study design and 
risk of bias
















Not assessed Not assessed Hospital:  RRb 0.67 (95% 
CI 0.59–0.77)




n = 116 (amiodarone)
n = 160 (landiolol)
Setting: Japan ICU
Not reported Retrospective com-
parative







Balik et al. (2017) n =  234d
n = 177 (amiodarone)




Septic shock Retrospective com-
parative
Risk of bias: Critical
Amiodarone versus 
metoprolol




Mieure et al. (2011) 
(conference abstract)
n =  126e
n = 61 (amiodarone)
n = 24 (metoprolol)
Setting: USA ICU
Not reported Retrospective com-
parative
Risk of bias: Critical
Amiodarone versus 
metoprolol
 < 100 bpm within 24 h 













Septic shock Retrospective com-
parative
Risk of bias: Critical
Amiodarone versus 
beta blockers (drug 
not specified)
Not assessed Not assessed NS
McKenzie Brown et al. 
(2018)
n =  33e
n = 6 (amiodarone)







Risk of bias: critical
Amiodarone versus 








Not compared between 
treatment groups
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much uncertainty due to the limited data reported [32] 
and small sample size [31]. Figure 2 shows rhythm con-
trol risk ratio results for studies comparing amiodarone 
with calcium channel blockers.
Beta blockers versus calcium channel blockers
One RCT [22] and three retrospective comparative 
studies [28, 31, 33] compared beta blockers with cal-
cium channel blockers (Table 3, Additional file 1: Tables 
S1, S2, S5 and S6). Balser et.al [22] conducted a RCT 
(n = 55) comparing esmolol with diltiazem in a noncar-
diac surgical population. Conversion to sinus rhythm was 
more common in the esmolol group at 2 h (59% vs 33%, 
p = 0.049); however there was no statistically significant 
difference at 12  h. There was also no evidence of a dif-
ference in hospital mortality [22]. This RCT was judged 
as having some concerns about possible bias primarily 
due to the lack of reporting of randomisation methods 
and the lack of blinding (Additional file 1). Another study 
[31] compared conversion rates in a surgical ICU popula-
tion but the sample size was too small to make any con-
clusions. Two retrospective comparative studies [28, 33] 
reported no evidence of a difference in hospital mortality.
Beta blockers versus digoxin
One large retrospective study [33] investigated the out-
comes in patients who received digoxin versus patients 
who received beta blockers (Additional file  1: Tables 
S5, S6, S13, and S4). Following propensity score match-
ing (n = 1932), hospital mortality was lower in patients 
who received beta-blockers compared to patients who 
received digoxin (RR 0.75 (95% CI: 0.64–0.88)). The 
study was judged as being at a serious risk of bias due 
to confounding (Additional file 1).
Hydrocortisone versus no treatment
One prospective study [25] and one retrospective study 
[29] compared hydrocortisone as a prophylactic treat-
ment with no treatment (Table  4, Additional file  1: 
Tables S3, S4, S5 and S6). Both studies [25, 29] were 
conducted in patients with septic shock. Launey et  al. 
(2019) reported that the unadjusted ICU and 28-day 
mortality in the hydrocortisone group was higher than 
when compared to the no treatment group (37% versus 
24% (p = 0.018); and 38% versus 26% (p = 0.036), respec-
tively), noting that patients who received hydrocortisone 
were more severely ill than those who did not receive 
hydrocortisone [25]. However, in the propensity score-
weighted analysis, patients who received hydrocortisone 
were less likely to develop NOAF compared to patients 
who did not [risk difference 11.9%, RR 0.58 (95% CI 0.35–
0.98)] [25]. This study [25] was judged to have serious 
risk of bias due to missing covariates in the propensity 
score matching. Similarly, the retrospective study [29] 
concluded that administering hydrocortisone was associ-
ated with a reduction in NOAF incidence. No evidence 
of a difference in mortality between the study groups was 
reported [29]. However, this study [29] was published as 
a conference abstract with limited data available and the 
dose of hydrocortisone was not reported [29].
Anticoagulation versus no treatment
Published comparative evidence for anticoagulation was 
very limited. One large retrospective study [34] found 
no benefit from in-hospital anticoagulation for NOAF 
in sepsis but was at high risk of bias (Additional file  1: 
Tables S5, S6 and S14). The study (n = 38,582 with any 
AF, n = 7522 with NOAF) [34] included hospitalised 
patients, around 60% of whom were treated on an ICU. 
Rates of in-hospital stroke were low in the NOAF cohort 





























Table 2 Studies comparing amiodarone and calcium channel blockers
a Randomised controlled trial
b Statistically not significant
c Includes beta blockers group
d Includes beta blockers group no treatment groups
Authors Sample size and setting Primary diagnosis Study design and risk 
of bias
Intervention Rate control outcome Rhythm control 
outcome
Mortality outcome
Delle Karth et al. (2001) n = 60
n = 20 (diltiazem)
n = 20 (amiodarone 
bolus)
n = 20 (amiodarone 
bolus and 24 h infu-
sion)
Setting: Austria ICU
Mixed cardiac and medi-
cal ICU population
RCT a
Risk of bias: high
Diltiazem versus ami-
odarone bolus versus 
amiodarone bolus 
and 24 h continuous 
infusion
Rate reduction within 
4 h:  NSb
Diltiazem: 70%
Amiodarone bolus: 55%
Amiodarone bolus with 
24 h continuous infu-
sion: 75%
Rate reduction within 
24 h:
Diltiazem versus 
amiodarone groups:  
p = .001
Amiodarone bolus ver-
sus amiodarone bolus 
with 24 h continuous 
infusion:  p = .08
Within 4 h: NS
Diltiazem: 30%
Amiodarone bolus: 40%
Amiodarone bolus with 
24 h continuous infu-
sion: 45%
Not assessed
Gerlach et al. (2008) n = 61
n = 55 NOAF patients
n = 28 (diltiazem)
n = 27 (amiodarone)




Risk of bias: Critical
Diltiazem versus ami-
odarone
Not assessed At 24 h: NS
Diltiazem: 87% Amiodar-
one: 87%









Septic shock Retrospective compara-
tive
Risk of bias: Critical
Calcium channel block-
ers (drug not specified) 
versus amiodarone
Not assessed Not assessed NS
Mieure et al. (2011) (con-
ference abstract)
n =  126c
n = 61 (amiodarone)
n = 41 (diltiazem)
Setting: USA ICU
Not reported Retrospective compara-
tive
Risk of bias: Critical
Diltiazem versus ami-
odarone






McKenzie Brown et al. 
(2018)
n =  33d
n = 6 (amiodarone)
n = 2 (calcium channel 
blockers)





Risk of bias: Critical
Calcium channel block-




































Table 3 Studies comparing beta blockers and calcium channel blockers
Randomised controlled trial
Statistically not significant
Includes amiodarone and digoxin groups
Relative risk
Includes amiodarone group and no treatment groups
Authors Sample size and 
setting
Primary diagnosis Study design and risk 
of bias
Intervention Rate control outcome Rhythm control 
outcome
Mortality outcome
Balser et al. (1998) n = 55
n = 28 (esmolol)




























Not assessed Not assessed Hospital:  RRd 
0.99 (95% CI: 
0.86–1.15)




Septic shock Retrospective com-
parative
Risk of bias: Critical
Beta blockers versus 
calcium channel 
blockers (drugs not 
specified)
Not assessed Not assessed NS
McKenzie Brown et al. 
(2018)
n =  33e
n = 22 (beta blockers)
n = 2 (calcium channel 
blockers)






Risk of bias: critical
Beta blockers versus 
calcium channel 
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(1.9%). As the hospital length of stay was not reported, 
the duration of exposure was unclear [34]. Following 
propensity score matching (n = 5585 analysed), rates of 
in-hospital ischaemic stroke events and risk of bleeding 
did not differ significantly between patients who did, and 
did not, receive parenteral anticoagulation. Given the low 
event rate, the study [34] may have had inadequate power 
to determine whether a significant difference exists.
Results from non‑comparative studies
The following pharmacological treatments were investi-
gated in non-comparative studies: amiodarone [5, 39, 41, 
43–45], magnesium-amiodarone step-up scheme [40], 
beta-blockers [5, 38, 41, 43], calcium channel blockers 
[5, 41, 43], digoxin [5, 41, 43], and ibutilide [35, 36]. Two 
non-comparative studies looked at electrical treatments 
[37, 42].
Two studies investigated anticoagulant therapy. One 
study reported a 5% risk of major bleeding with IV hepa-
rin, though thromboembolism events were not reported 
[39]. Another study reported a 9% (5/58) risk of major 
bleeding with therapeutic anticoagulation in patients 
with NOAF and pre-existing AF [5] with no strokes 
occurring during ICU admission.
Details of non-comparative studies are reported in 
Additional file 1: Tables S7, S8, S9 and S10.
Results from review articles, surveys, and opinion pieces
A full summary of the reviews, surveys and opinion 
pieces identified in the review is reported in Additional 
file 1.
Reported recommendations for future research
Most studies and review articles that were included in 
this review concluded that further prospective research 
accounting for confounding factors is required to deter-
mine the success and clinical implications of prophylac-
tic and treatment strategies in patients treated in an ICU 
with NOAF [5, 6, 14, 22, 24, 25, 28, 29, 32, 33, 38, 40, 41, 
43, 46–52]. It was emphasised that optimal regimens and 
best dosing strategies for treatments are yet to be estab-
lished [31, 37, 45]. Eight studies [23, 26, 27, 30, 35, 36, 39, 
44] and four review articles [53–56] did not provide any 
recommendations for future research.
Discussion
The evidence base for NOAF management for patients 
in ICU was limited. Many studies identified in this scop-
ing review were non-comparative studies (i.e. lacking a 
comparator group, n = 12). Of the 25 primary studies 
included in the review only two were RCTs [22, 23] and 
only three of the non-randomised comparative studies 
[25, 33, 34] attempted to control for confounding factors. 
In the studies which used more robust approaches, there 
were nevertheless still concerns about how bias (arising 
from their designs and/or analyses) might affect their 
results. Moreover, considerable heterogeneity defining 
NOAF, treatment doses (e.g. total dose ranging from less 
than a gram to eight grams for amiodarone) [5, 23, 24, 
26, 30, 44, 45], administration (e.g. bolus or continuous 
infusion), and timepoints to assess conversion to sinus 
rhythm (e.g. within two [22], four [23], 12 [23], and 24 h 
[5, 24, 26, 32] was observed across studies. Similarly, a 
systematic review was not able to make evidence-based 
recommendations for pharmacologic rhythm conversion 
strategies for patients who develop NOAF in a general 
ICU due to considerable methodological heterogeneity 
of the included studies [48]. There is therefore a need to 
establish optimal treatment dosing and administration 




Authors Sample size and 
setting
Primary diagnosis Study design and 
risk of bias
Intervention Incidence of 
NOAF
Mortality outcome
Launey et al. (2019) n = 261
n = 123 (hydrocor-
tisone)
n = 138 (no treat-
ment)
Setting: France ICU
Septic shock Prospective com-
parative
Risk of bias: serious
Hydrocortisone vs 
no treatment
RDa − 11.9% (95% 
CI − 23.4% to − 
0.5%)












n = 39 (hydrocorti-
sone)
Setting: USA ICU
Septic shock Retrospective 
comparative
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regimens, as well as standardised and validated outcome 
measures of treatment success.
The limited evidence from this review [26, 30, 32] 
suggests that beta-blockers may be equivalent to ami-
odarone for rhythm control. Where reduced mortality 
in those who received beta-blockers compared to those 
who received amiodarone was reported [26, 33], there 
were significant concerns about bias. Despite this, some 
review articles [46, 50, 51] argued that beta blockers may 
be a reasonable first-choice treatment due to the current 
evidence of decreased mortality [46], and improved heart 
rate control [46, 50]. Two opinion pieces [14, 57] also 
favoured the use of beta-blockers as the initial pharmaco-
therapy, given the limited and indirect evidence. In con-
trast, five reviews discussed amiodarone as a potentially 
effective treatment [47, 49, 52–54], though it was also 
recognised that amiodarone has potentially significant 
side effects [47, 52, 54].
Calcium channel blockers appeared to be less effective 
for conversion to sinus rhythm when compared with beta 
blockers, and result in more hypotension than amiodar-
one [22, 23]. Two studies [25, 29] reported that hydro-
cortisone may be effective as a prophylactic treatment. 
However, these results are subject to much uncertainty 
due to methodological limitations.
International guidelines [12, 13] provide advice regard-
ing the management of patients presenting acutely with 
AF, and/or patients with AF with haemodynamic insta-
bility. However, the evidence base and expert consensus 
on which these guidelines are based does not appear 
to include patients in the intensive care unit setting. 
Therefore, whilst they may be used to guide some gen-
eral aspects of AF management in any patient, such as 
the recommendation to use cardioversion if the patient 
is acutely haemodynamically unstable, recommendations 
regarding pharmacological therapy and whether or not 
the patient should be anticoagulated, either short or long-
term, may not apply to this specific patient population.
Comparative evidence for or against electrical cardio-
version for patients in ICU with NOAF was not identified 
in our review. Electrical cardioversion should be con-
sidered in patients where AF is contributing to marked 
haemodynamic instability. NOAF often occurs alongside 
haemodynamic instability but is more likely to be a sig-
nificant contributor where ventricular rates are very high 
or where there is underlying structural heart disease. As 
with other treatments, electrical cardioversion should be 
used alongside aggressive management of underlying AF 
drivers. Further procedural considerations are detailed 
elsewhere [58].
It is unclear whether to administer therapeutic antico-
agulation in critically ill patients with NOAF for stroke 
prevention. Limited evidence suggests bleeding risk 
outweighs the increased risk of thromboembolism whilst 
in ICU [5, 39], but optimal timing of anticoagulation is 
unknown [34, 52]. Two review articles [51, 56] proposed 
a patient-centred approach to only administer anticoag-
ulants in patients with high risk of arterial thromboem-
bolic events. Notably, 64% of respondents of a UK wide 
survey [17] reported that they would not use anticoagu-
lant therapy in critically ill patients with NOAF.
Included studies were consistent in recommending 
further research as optimal management strategies have 
yet to be determined. Findings from previous studies of 
NOAF in patients in ICU may have been affected by the 
heterogeneity of patients in a general ICU. Future stud-
ies of narrower populations may therefore be helpful to 
determine best practice in specific clinical scenarios.
Conclusions
Our systematic scoping review focusses on the compara-
tive evidence for treatment of NOAF in patients in ICU. 
Interpretation of the evidence is limited due to study 
design flaws and important differences in definitions of 
NOAF, outcomes and treatment dose. Calcium chan-
nel blockers may result in more cardiovascular instabil-
ity and slower rhythm control than amiodarone or beta 
blockers. More evidence is required about risk of bleed-
ing and thromboembolism in the short and long term 
after NOAF onset. However, the little evidence available 
does not support therapeutic anticoagulation for NOAF 
whilst patients are critically ill. International guidelines 
regarding management of AF are largely based on studies 
and expert consensus that may not be applicable to this 
specific patient population. Given the significant mor-
bidity and mortality associated with NOAF, adequately 
powered RCTs are needed to inform management of this 
common phenomenon. Consensus definitions of NOAF, 
and of treatment success will improve future studies.
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